Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

医学 奥曲肽 安慰剂 神经内分泌肿瘤 中期分析 内科学 胃肠病学 肿瘤进展 临床终点 生长抑素 危险系数 原发性肿瘤 安慰剂对照研究 转移 肿瘤科 癌症 随机对照试验 病理 双盲 置信区间 替代医学
作者
Anja Rinke,Hans‐Helge Müller,Carmen Schade‐Brittinger,Klaus‐Jochen Klose,Peter Barth,M. Wied,Christina Mayer,Behnaz Aminossadati,Ulrich‐Frank Pape,Michael Bläker,Jan Harder,Christian Arnold,Thomas M. Gress,R. Arnold
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:27 (28): 4656-4663 被引量:2154
标识
DOI:10.1200/jco.2009.22.8510
摘要

Somatostatin analogs are indicated for symptom control in patients with gastroenteropancreatic neuroendocrine tumors (NETs). The ability of somatostatin analogs to control the growth of well-differentiated metastatic NETs is a matter of debate. We performed a placebo-controlled, double-blind, phase IIIB study in patients with well-differentiated metastatic midgut NETs. The hypothesis was that octreotide LAR prolongs time to tumor progression and survival.Treatment-naive patients were randomly assigned to either placebo or octreotide LAR 30 mg intramuscularly in monthly intervals until tumor progression or death. The primary efficacy end point was time to tumor progression. Secondary end points were survival time and tumor response. This report is based on 67 tumor progressions and 16 observed deaths in 85 patients at the time of the planned interim analysis.Median time to tumor progression in the octreotide LAR and placebo groups was 14.3 and 6 months, respectively (hazard ratio [HR] = 0.34; 95% CI, 0.20 to 0.59; P = .000072). After 6 months of treatment, stable disease was observed in 66.7% of patients in the octreotide LAR group and 37.2% of patients in the placebo group. Functionally active and inactive tumors responded similarly. The most favorable effect was observed in patients with low hepatic tumor load and resected primary tumor. Seven and nine deaths were observed in the octreotide LAR and placebo groups, respectively. The HR for overall survival was 0.81 (95% CI, 0.30 to 2.18).Octreotide LAR significantly lengthens time to tumor progression compared with placebo in patients with functionally active and inactive metastatic midgut NETs. Because of the low number of observed deaths, survival analysis was not confirmatory.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
青黛完成签到 ,获得积分10
2秒前
大橙子发布了新的文献求助10
6秒前
领导范儿应助科研通管家采纳,获得10
7秒前
量子星尘发布了新的文献求助10
11秒前
明钟达完成签到 ,获得积分10
19秒前
byyyy完成签到,获得积分10
22秒前
高高的哈密瓜完成签到 ,获得积分10
26秒前
Rondab应助橙汁采纳,获得10
29秒前
读书的时候完成签到,获得积分10
31秒前
颜云尔完成签到,获得积分10
42秒前
孤独雨梅完成签到,获得积分10
45秒前
woobinhua完成签到 ,获得积分10
45秒前
雪落你看不见完成签到,获得积分10
47秒前
十月天秤完成签到,获得积分0
48秒前
依文完成签到,获得积分20
48秒前
ymr完成签到 ,获得积分10
49秒前
哦哦哦完成签到 ,获得积分10
50秒前
jzmupyj完成签到,获得积分10
50秒前
大橙子发布了新的文献求助10
53秒前
xdlongchem完成签到,获得积分10
54秒前
量子星尘发布了新的文献求助10
56秒前
小梦完成签到,获得积分10
57秒前
xuhang完成签到,获得积分10
57秒前
ZSHAN完成签到,获得积分10
58秒前
美满的机器猫完成签到,获得积分10
1分钟前
王小磊完成签到,获得积分10
1分钟前
谢花花完成签到 ,获得积分10
1分钟前
1分钟前
瓦罐完成签到 ,获得积分10
1分钟前
扁舟灬完成签到,获得积分10
1分钟前
Cpp完成签到 ,获得积分10
1分钟前
贤惠的老黑完成签到 ,获得积分10
1分钟前
ame1120发布了新的文献求助10
1分钟前
倦梦还完成签到,获得积分10
1分钟前
Sunrise完成签到,获得积分10
1分钟前
yyyy发布了新的文献求助10
1分钟前
自觉柠檬完成签到 ,获得积分10
1分钟前
ergatoid完成签到,获得积分10
1分钟前
Hao完成签到,获得积分10
1分钟前
月亮煮粥完成签到,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038128
求助须知:如何正确求助?哪些是违规求助? 3575831
关于积分的说明 11373827
捐赠科研通 3305610
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022